Drug Trial Radar · NCT02386358
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
Last checked: Nov 20, 2026Latest source record: Mar 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
910
Actual
Start
Mar 1999
Primary completion
Dec 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- Instituto Nacional de Parasitologia Dr. Mario Fatala ChabenGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- National Council of Scientific and Technical Research, Argentina; Pan American Health Organization; Becas Carrillo Oñativia, Ministerio de Salud, Argentina; Drugs for Neglected Diseases
- First posted
- Mar 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is: 1. -to determine whether benznidazole (BZN) will be able to modify the natural evolution of chronic Chagas disease in adult patients by means of a randomized, double-blind clinical trial (RCT). Also: 2. -to validate therapeutic efficacy with new methods, such as recombinant antigen F29 of Trypanosoma cruzi visualized by conventional ELISA, in the context of the RCT compared with conventional serology (CS) 3. -to develop the real-time polymerase chain-reaction (RT-PCR) to quantify the parasite load as an early therapeutic effect. 4. to determine the potential of such serological and parasitological methods as predictors of therapeutic effect or failure.
Conditions
- Chagas Disease
Interventions
BenznidazoleDrug
Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
PlaceboDrug
Placebo at a dose 5 m/Kg/day until 60 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiovascular MortalityTime frame: Time to event: from date of randomization until the date of first documented progression or date of death from any cause up to 10 years of follow-up
- Development of heart failureTime frame: Time to event: from date of randomization until the date of first documented progression of heart failure up to 10 years of follow-up
- Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillatorTime frame: Time to event: from date of randomization until the date of first documented progression up to 10 years of follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instituto Nacional de Parasitología Dr Mario Fatala Chaben
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.